IT IS THE purpose of this paper to present an evaluation of the therapeutic efficacy of phenylbutazone* in Hodgkin's disease. The study covers a period of 18 months, during which time sufficient data were accumulated on 35 patients with Hodgkin's disease to make evident a pattern of therapeutic response and to delimit its usefulness insofar as this disease is concerned.
We shall not review the literature pertaining to the chemistry or pharmacology of phenylbutazone nor its effects on diseases other than Hodgkin's disease. This has been done adequately by others,† but up to now only one reference3 has appeared in the literature as to its effect on Hodgkin's disease. This one report states briefly that after a single intramuscular injection of the drug into one patient with Hodgkin's disease there followed reduction of fever, subsidence of pain, and improvement of general condition and appetite.
In Table 1 are
A. ROTTINO, A. JOFFE, G. HOFFMANN. PHENYLBUTAZONE (BUTAZOLIDIN), A USEFUL CHEMOTHERAPEUTIC AGENT FOR HODGKIN'S DISEASE. AMA Arch Intern Med. 1954;93(4):561–570. doi:10.1001/archinte.1954.00240280081009